Cannabis Sativa, Inc.: insider trades · United States · SEC (Form 4)

About Cannabis Sativa, Inc.

Cannabis Sativa, Inc. (ticker: CBDS) is a U.S.-based reporting company with a long history as a microcap tied to the cannabis, telemedicine and intellectual-property space, although its recent filings show a broader strategic shift. The company was incorporated in Nevada in November 2004 under the name Ultra Sun Corp. and changed its name to Cannabis Sativa, Inc. in November 2013. Its headquarters are in Mesquite, Nevada, United States, and it continues to be associated with the CBDS ticker in SEC filings and market references. In its most recent SEC disclosures, the company states that its primary operating activity has been conducted through PrestoCorp, a majority-owned subsidiary that provides online telemedicine and referral services for customers seeking medical marijuana cards in jurisdictions where medical cannabis is legal. The company also maintains several other subsidiaries and assets geared toward brand development, patents, trademarks, and CBD-related product opportunities, including Wild Earth Naturals, Hi Brands, KPAL, and Eden Holdings. From an industry perspective, Cannabis Sativa remains a highly speculative small-cap name with limited scale, a thin operating footprint, and a long record of losses and funding dependence. The SEC filings indicate that the business has relied heavily on advances from related parties, stock-based compensation, and other non-traditional financing mechanisms to sustain operations. That makes the balance sheet and capital structure important to monitor, especially for equity investors. Competitive positioning is therefore best described as niche and opportunistic rather than established leadership: the company is not a dominant cannabis operator, but rather a small platform seeking to monetize telemedicine services, hemp/CBD-related intellectual property, and potentially new brand or acquisition opportunities. Recent developments matter. In 2024 and 2025, management said it was actively reviewing acquisition prospects and new product/brand development opportunities. A major corporate event also occurred in November 2024, when the company changed its name to Dogecoin Cash, Inc., signaling a strategic pivot beyond its legacy cannabis identity. For investors analyzing CBDS, the key takeaway is that this remains a U.S. reporting issuer with SEC disclosure obligations, including insider Form 4 activity, but the business profile is that of a transformation story rather than a mature operating franchise. The company should be viewed as high risk, dilution-prone, and highly dependent on execution, financing availability, and the successful conversion of intangible assets or strategic initiatives into sustainable revenue.